Extracorporeal CO₂ Removal Devices Market By Product (Dedicated ECCO₂R Systems, Integrated ECCO₂R and CRRT Systems, Gas-Exchange Membranes and Cartridges, Blood Circuits, Tubing, and Filters, Cannulae and Catheters, Other Accessories and Consumables); By Application (Acute Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease Exacerbations, Acute Respiratory Distress Syndrome, Lung-Protective Ventilation Support, Bridge to ECMO or Lung Recovery, Combined Respiratory and Renal Support); By End User (Hospitals and Intensive Care Units, Specialized Respiratory and Critical-Care Centres, Academic Medical Centres, Clinical Research Institutes); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Extracorporeal CO2 Removal Devices Market: ECMO Infrastructure Expands, but ECCO2R Still Faces an Outcome and Reimbursement Test

The Global Extracorporeal CO2 Removal Devices Market is projected to grow at an 11.7% CAGR, expanding from USD 244.06 million in 2025 to USD 529.51 million by 2032, according to Strategic Market Research.

 

Extracorporeal CO2 removal, or ECCO2R, occupies a narrow position between conventional ventilation and full extracorporeal membrane oxygenation. Intensive-care teams may consider the technology when a patient cannot remove enough carbon dioxide without increasingly aggressive ventilation. Revenue is generated through access to an extracorporeal platform and repeat use of gas-exchange membranes, tubing, cannulae, filters, and other disposable components.

 

Market growth cannot be estimated directly from COPD, acute respiratory distress syndrome, or respiratory-failure prevalence. Only a small proportion of these patients fail conventional support, remain suitable for vascular access and anticoagulation, reach a specialist ICU, and receive approval from physicians, hospitals, and payers. The addressable patient population is therefore much smaller than the underlying respiratory-disease burden.

 

ECCO2R Sits Below Full ECMO Support

ECMO temporarily performs part of the work of severely failing lungs or both the heart and lungs. VV-ECMO primarily supports respiratory function, while VA-ECMO provides both respiratory and circulatory support. Hospitals use these systems in severe respiratory failure, cardiac failure, pulmonary embolism, transplant pathways, major surgery, and selected resuscitation cases. More than 23,000 ECMO runs were reported globally in 2024, showing that extracorporeal support has moved beyond a small group of pioneering centres.

ECCO2R does not provide the same level of support. It mainly removes carbon dioxide at lower blood-flow rates and offers little or no direct oxygenation or cardiac assistance. Smaller cannulae and lower flow requirements may reduce some of the operational burden associated with ECMO, but patients still require extracorporeal blood circulation, systemic anticoagulation, specialist monitoring, and rapid management of bleeding, thrombosis, infection, or circuit failure.

The distinction is commercially important. ECMO procedure growth expands the number of hospitals with trained perfusionists, extracorporeal-support protocols, oxygenator supply chains, and critical-care infrastructure. It does not establish an equivalent ECCO2R treatment volume. Suppliers can use the ECMO hospital network to identify capable customers, but they still need a separate clinical and economic case for carbon-dioxide-removal therapy.

 

ECMO Growth Creates Infrastructure but Also Sets a High Investment Threshold

Adult ECMO use increased substantially after evidence supporting its use in severe respiratory failure emerged in 2009. ELSO registry research recorded 154,568 ECMO runs from 2009 to 2022, including 108,265 adult cases. Adult runs increased from 851 in 2009 to 17,975 in 2021.

Hospitals entering extracorporeal care have invested in pumps, oxygenators, cannulae, blood monitoring, transport equipment, emergency power, perfusion staff, specialist nursing, intensive-care training, and multidisciplinary governance. These capabilities reduce the operating barriers for ECCO2R suppliers targeting established ECMO or continuous renal replacement therapy centres.

High-acuity extracorporeal programs remain costly and labour-intensive. The Advisory analysis reported that median US hospital charges for ECMO reached USD 550,000 in 2014 and cautioned that complex staffing and infrastructure made ECMO unsuitable as an investment for every hospital. Although the figure is historical and should not be treated as a current treatment cost, it demonstrates why hospital committees scrutinize patient selection and outcomes before supporting another extracorporeal platform.

ECCO2R suppliers face the same institutional review without ECMO’s wider range of respiratory and cardiac indications. Dedicated equipment can remain underused when eligible cases are infrequent, leaving hospitals with training, maintenance, and service costs that cannot be distributed across enough procedures.

 

The Best-Case Pathway Is Avoiding More Invasive Respiratory Support

ECCO2R has its strongest clinical and commercial case when controlled carbon-dioxide removal allows physicians to reduce damaging ventilation intensity or avoid escalation to invasive mechanical ventilation. A successful treatment episode could reduce ventilator complications, shorten ICU care, or prevent progression to higher-cost ECMO.

Severe respiratory admissions provide the upstream need. Diagnosed COPD affected 3.8% of US adults in 2023. England recorded 118,975 emergency COPD admissions in the financial year ending 2025, while Australia reported approximately 159,000 COPD-related hospitalizations during 2023–24. Australian admissions represented 337,000 bed days and an average stay of 5.4 days.

Most of these patients never become ECCO2R candidates. Medicines, oxygen, non-invasive ventilation, and mechanical ventilation manage much of the hospital population. Suppliers gain more from mapping tertiary respiratory ICUs and research networks than from treating national COPD prevalence as a procedure forecast.

Hospitals are also likely to restrict treatment to patients with reversible respiratory failure, severe carbon-dioxide retention, acceptable bleeding risk, and a realistic route to recovery. Treatment without a defined endpoint can consume filters, ICU capacity, and clinical labour without improving discharge outcomes.

 

Randomized Trials Turned Broad Adoption into a Research Market

The REST trial tested whether ECCO2R could support lower-intensity ventilation in 412 adults with acute hypoxemic respiratory failure. Ninety-day mortality reached 41.5% in the ECCO2R group and 39.5% with standard care. The study was stopped early for futility and feasibility, leaving payers and hospitals without evidence of a mortality advantage in a major proposed indication.

VENT-AVOID examined ECCO2R in COPD patients receiving non-invasive or invasive ventilation. The trial enrolled 113 patients across 41 US institutions between 2018 and 2022, below the planned 180. Treatment did not significantly improve ventilator-free days during the first five days. Slow recruitment across a large hospital network also indicates that the eligible population is difficult to identify consistently.

NICE recommends against ECCO2R for acute hypoxic respiratory failure and permits its use in acute hypercapnic respiratory failure only through research. Treatment should take place in specialist intensive-care centres with multidisciplinary patient selection and trained teams. The recommendation directs UK purchasing toward trials and research-active hospitals rather than routine NHS adoption.

Suppliers now need studies that connect carbon-dioxide removal with outcomes valued by hospital buyers. Lower carbon-dioxide levels or reduced ventilator settings will not be enough unless they lead to fewer intubations, shorter ventilation, fewer ICU days, lower ECMO escalation, or reduced total treatment costs.

 

US Clearance Did Not Secure Routine Commercial Adoption

The FDA established a Class II ECCO2R category under product code QOH when it authorized the Hemolung Respiratory Assist System in 2021. The device was indicated for up to five days in adults with acute, reversible respiratory failure when other treatment options could not safely or adequately control carbon dioxide and deterioration was expected.

The FDA reviewed evidence covering 1,034 Hemolung treatments. A total of 121 patients experienced 172 therapy-related complications, 96 complications required medical intervention, and ten were associated with death. The evidence included clinical trials, expanded-access treatments, registry cases, and post-market experience rather than one consistent randomized population.

Regulatory authorization created a route for future substantially equivalent products but did not guarantee payment or hospital purchasing. CMS approved a maximum new-technology add-on payment of USD 6,500 for qualifying Hemolung cases in fiscal year 2023, based on an applicant-estimated cost of USD 10,000 per treatment. The payment was temporary, product-specific, and separate from permanent national coverage.

Anthem’s policy, reviewed in January 2026, classifies ECCO2R as investigational and not medically necessary for all indications. Hospitals treating commercially insured patients may therefore face payment uncertainty even when an ICU team considers therapy clinically appropriate.

LivaNova discontinued Hemolung operations during 2024 as part of the wind-down of its Advanced Circulatory Support business. The business represented approximately 4% of company revenue during the first nine months of 2023, while LivaNova expected impairment and restructuring charges from the wider exit. FDA clearance and historical Medicare support were not enough to sustain a specialized platform with limited use and high service requirements.

 

Filters Generate Repeat Revenue, but Clotting Weakens the Hospital Case

A prospective French study published in 2026 treated 58 patients across ten centres using PrismaLung+. Forty-two received standalone ECCO2R, while 16 received ECCO2R together with continuous renal replacement therapy. The study used 91 filters, equal to approximately 1.57 filters per patient.

Average circuit life was 32 hours. Standalone treatment averaged 27.5 hours, compared with 46.8 hours when ECCO2R was combined with renal replacement therapy. Longer treatments or early filter failure can push disposable use above one unit per patient, creating recurring revenue for manufacturers.

Poor circuit reliability turns repeat consumption into a hospital objection. Clotting affected 15 of the 58 patients, and seven discontinued therapy because of clotting. Hospitals absorb the cost of wasted filters, replacement procedures, treatment interruption, and additional nursing work.

Suppliers that extend circuit life may generate fewer disposable sales during a single case but achieve better long-term economics through higher treatment completion, protocol approval, and repeat hospital ordering. Procurement committees are unlikely to reward replacement volume caused by product or anticoagulation problems.

 

ECMO Companies Shape the Adjacent Competitive Landscape

Getinge supplies portable extracorporeal heart-lung support platforms for hospital care and patient transport. Its established ECMO presence gives the company access to specialist critical-care centres, trained teams, oxygenator procurement, and service relationships that could support related extracorporeal technologies.

Medtronic launched the VitalFlow ECMO System in the United States in September 2024 and received a European CE Mark in June 2025. A transport frame cleared in Europe in May 2026 extended the system into ambulance and aircraft movement. Medtronic’s acquisition of MC3 Cardiopulmonary also brought oxygenators, catheters, and ECMO development capabilities under a larger cardiovascular supplier.

Fresenius Medical Care and Xenios compete through the Novalung platform. The FDA cleared Novalung in 2020 as the first ECMO system authorized in the United States for more than six hours of extracorporeal life support. Fresenius strengthened hospital access in November 2024 through a purchasing agreement with Premier.

Terumo and LivaNova have substantial cardiopulmonary bypass, oxygenator, pump, and perfusion portfolios. Their manufacturing expertise is relevant to gas-exchange membranes and extracorporeal circuits, although individual product indications and permitted operating periods vary. These companies should not automatically be classified as direct ECCO2R leaders without product-level utilization or revenue evidence.

Eurosets introduced Xtreme Rescue in 2025 as a portable ECLS device weighing less than seven kilograms, with approximately 200 minutes of internal battery autonomy. MicroPort acquired Hemovent for up to EUR 123 million in 2021, adding the pneumatic MOBYBOX ECLS platform to its critical-care portfolio. Both developments reflect supplier investment in smaller and more mobile extracorporeal systems, but neither provides direct evidence of current ECCO2R market share.

 

Hospitals Purchase an Extracorporeal Program, Not Only a Device

ECCO2R procurement involves intensivists, pulmonologists, ICU nurses, renal-therapy teams, perfusionists, infection-control staff, risk managers, finance committees, and payers. Suppliers may need to support treatment protocols, staff simulation, patient selection, emergency troubleshooting, anticoagulation management, and replacement-part availability before the first commercial case occurs.

Manufacturers with existing ECMO or renal-replacement operations can distribute training and service costs across a larger critical-care portfolio. Integrated ECCO2R systems may also use equipment already present in the ICU, reducing the risk of purchasing a dedicated console that remains idle.

Academic centres, tertiary respiratory ICUs, ECMO hospitals, and facilities operating compatible CRRT platforms represent the most defensible customer base. General hospitals without specialist teams will remain difficult to convert until clinical outcomes and reimbursement improve.

The projected 11.7% CAGR will be supported by specialist-centre expansion, repeat disposable use, platform integration, and continued research into ventilation-sparing care. Broad adoption still depends on better patient selection, more reliable circuits, payer recognition, and proof that treatment reduces hospital resource use. Companies that connect ECCO2R with existing extracorporeal infrastructure and measurable ICU savings will be better positioned than vendors relying only on physiological carbon-dioxide removal.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 244.06 Million
Revenue Forecast in 2032	USD 529.51 Million
Overall Growth Rate	CAGR of 11.7% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Dedicated ECCO2R Systems, Integrated ECCO2R and CRRT Systems, Gas-Exchange Membranes and Cartridges, Blood Circuits, Tubing, and Filters, Cannulae and Catheters, Other Accessories and Consumables
By Application	Acute Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease Exacerbations, Acute Respiratory Distress Syndrome, Lung-Protective Ventilation Support, Bridge to ECMO or Lung Recovery, Combined Respiratory and Renal Support
By End User	Hospitals and Intensive Care Units, Specialized Respiratory and Critical-Care Centres, Academic Medical Centres, Clinical Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising burden of acute hypercapnic respiratory failure, growing COPD exacerbation admissions, wider use of lung-protective ventilation in ICUs, expanding need for bridge support before ECMO or lung recovery, and increasing adoption of combined respiratory and renal support platforms
Customization Option	Available upon request